Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc
默沙東的Keytruda®（帕博利珠單抗）在中國獲批與化療聯合用於新輔助治療，手術後繼續作爲單藥治療，作爲可切除II期、IIIa或IIIb非小細胞肺癌患者的輔助治療。
